期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 16, 页码 -出版社
MDPI
DOI: 10.3390/ijms22168996
关键词
CAR T-cells; hematological malignancies; leukemia; lymphoma
资金
- Austrian Science Fund (FWF)
- Austrian science fund FWF [P32762-B, W1213]
- Cancer Cluster Salzburg [20102-P1509466-FPR01-2015, 20102-P1601064-FPR01-2017]
- Paracelsus Medical University [PMU-FFF E-20/32/168-GEI]
- Austrian Science Fund (FWF) [P32762] Funding Source: Austrian Science Fund (FWF)
CAR T-cells are a promising therapeutic approach for hematological malignancies, particularly in lymphoma and acute lymphocytic leukemia. Despite encouraging clinical results, challenges remain in treating other hematological malignancies.
Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach in treating hematological malignancies. CAR T-cells represent engineered autologous T-cells, expressing a synthetic CAR, targeting tumor-associated antigens (TAAs) independent of major histocompatibility complex (MHC) presentation. The most common target is CD19 on B-cells, predominantly used for the treatment of lymphoma and acute lymphocytic leukemia (ALL), leading to approval of five different CAR T-cell therapies for clinical application. Despite encouraging clinical results, treatment of other hematological malignancies such as acute myeloid leukemia (AML) remains difficult. In this review, we focus especially on CAR T-cell application in different hematological malignancies as well as strategies for overcoming CAR T-cell dysfunction and increasing their efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据